Does Rallies show 13F holders for RMD?

Yes. Rallies tracks hedge fund and 13F ownership data for RMD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RMD. It does not provide personalized investment advice.

RMD (ResMed Inc.) Stock Analysis - Hedge Fund Holdings

ResMed Inc. (RMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RMD trades at $210.64 with a market cap of $29.61B and a P/E ratio of 20.24. RMD moved +1.11% today. Year to date, RMD is -14.47%; over the trailing twelve months it is -15.43%. Its 52-week range spans $198.61 to $293.81. Analyst consensus is buy with an average price target of $264.56. Rallies surfaces RMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RMD stock?

Hedge funds tracked by Rallies that own RMD include Coatue Management, Pinebridge Investments, Bridgewater Associates, Panagora Asset, and Maverick Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ResMed Inc..

RMD Key Metrics

Key financial metrics for RMD
Metric	Value
Price	$210.64
Market Cap	$29.61B
P/E Ratio	20.24
EPS	$10.41
Dividend Yield	0.60%
52-Week High	$293.81
52-Week Low	$198.61
Volume	146
Avg Volume	0
Revenue (TTM)	$5.54B
Net Income	$1.52B
Gross Margin	61.59%

Top Hedge Funds Holding RMD

Coatue Management holds 473.18K shares of RMD, changed +0.00% as of Sep 30, 2024.
Pinebridge Investments holds 139.07K shares of RMD, changed -24.34% as of Sep 30, 2025.
Bridgewater Associates holds 39.24K shares of RMD, changed +19.17% as of Mar 31, 2026.
Panagora Asset holds 4.08K shares of RMD, changed +0.00% as of Mar 31, 2026.
Maverick Capital holds 1.91K shares of RMD, changed +0.00% as of Mar 31, 2024.

Latest RMD News

ResMed slides after Q3 beat as investors eye costs and post-earnings positioning — May 1, 2026
ResMed’s AirTouch N30i Mask Gains 6% Compliance Lift, Noctrix Acquisition Raises Margins — May 1, 2026
ResMed slides 3% after Q3 earnings: beat on sales, but costs and outlook worry — Apr 30, 2026
ResMed CFO Brett Sandercock Retires After 20 Years; Aaron Bloomer Appointed — Apr 30, 2026
ResMed’s $255 Price Target Signals 11.7% Upside as Insiders Sell $1.5M Shares — Apr 13, 2026

Recent RMD Insider Trades

Farrell Michael J. sold 4.99K (~$1.04M) on May 7, 2026.
Farrell Michael J. sold 4.99K (~$1.13M) on Apr 7, 2026.
Sandercock Brett sold 1.00K (~$224.31K) on Apr 1, 2026.

RMD Analyst Consensus

13 analysts cover RMD: 0 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.56.

Common questions about RMD

Who owns RMD stock?: Hedge funds tracked by Rallies that own RMD include Coatue Management, Pinebridge Investments, Bridgewater Associates, Panagora Asset, and Maverick Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ResMed Inc..
Does Rallies show 13F holders for RMD?: Yes. Rallies tracks hedge fund and 13F ownership data for RMD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RMD. It does not provide personalized investment advice.